vimarsana.com
Home
Live Updates
Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinsons Disease : comparemela.com
Inhibikase Therapeutics Provides Safety and Functional Update on its Phase 1/1b 101 Trial and its Phase 2 IkT-148009 201 Trial in Parkinson's Disease
/PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase...
Related Keywords
Atlanta ,
Georgia ,
United States ,
Massachusetts ,
Boston ,
American ,
Miltonh Werner ,
Stroy Freeman ,
Alex Lobo ,
Milton Werner ,
Twitter ,
Facebook ,
Inhibikase Or Company ,
Nasdaq ,
Inhibikase Therapeutics Inc ,
Exchange Commission ,
Linkedin ,
American Academy Of Neurology ,
Parkinson Progression Marker Initiative ,
Company Contact ,
Youtube ,
Sternir Inc ,
Inhibikase Therapeutics ,
Abelson Tyrosine Kinases ,
Progression Marker Initiative ,
Lancet Neurology ,
American Academy ,
Inhibikase Director ,
Non Motor Symptom Score ,
Abelson Tyrosine Kinase ,
Ableson Tyrosine ,
Multiple System Atrophy ,
Private Securities Litigation Reform Act ,
Nc ,
comparemela.com © 2020. All Rights Reserved.